Glaxosmithkline Pharmaceuticals Ltd. (BSE: 500660) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹44,982 Cr, it ranks #221 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 9 in Non-Prescription Drugs. At ₹2,665.40 (as of 16 Nov 2026), the share price is 14.6% below its 52-week high of ₹3,120.70 and 27.6% above its 52-week low of ₹2,088.10. The share price is up 3.3% over one year and up 0.2% over three months.
| Current Price | ₹2,665.40 |
|---|---|
| Market Cap | ₹44,982 Cr |
| BSE Code | 500660 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 43.4 |
| Return on Equity | 48.91% |
| Return on Assets | 18.50% |
| 52-Week Range | ₹2,088.10 – ₹3,120.70 |
| 1-Year Price Change | +3.3% |
| 3-Month Price Change | +0.2% |
| Beta (1Y) | 0.44 |
| Dividend Yield | 2.15% |
| Headquarters | Mumbai, Maharashtra |
| Website | india-pharma.gsk.com |
| Revenue | ₹1,184 Cr |
|---|---|
| Net Profit | ₹336 Cr |
| Net Margin | 28.4% |
| EPS (Basic) | ₹19.83 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹1,184 Cr in Q2 FY27, up 20.8% from ₹980 Cr in Q2 FY26 and up 26.1% from ₹938 Cr in Q1 FY27. It posted a net profit of ₹336 Cr for the quarter, against a net profit of ₹257 Cr in Q2 FY26 (up 30.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹805 Cr (Q1 FY26) to ₹1,184 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,184 Cr | ₹336 Cr | 28.4% |
| Q1 FY27 | ₹938 Cr | ₹237 Cr | 25.3% |
| Q4 FY26 | ₹995 Cr | ₹278 Cr | 27.9% |
| Q3 FY26 | ₹1,041 Cr | ₹296 Cr | 28.4% |
| Q2 FY26 | ₹980 Cr | ₹257 Cr | 26.3% |
| Q1 FY26 | ₹805 Cr | ₹205 Cr | 25.5% |
| Q4 FY25 | ₹974 Cr | ₹263 Cr | 27.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 75.00% of Glaxosmithkline Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 55.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating ch
1. Pharmaceuticals-This segment manufactures, distributes, and trades in pharmaceuticals. 2. Other businesses-This segment provides diagnostics and laboratory equipments. It also engages in the research and development of medicines. 3. Corporate-0 4. Segment Adjustment-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Glaxosmithkline Pharmaceuticals Ltd. is trading at ₹2,665.40, with a market capitalisation of ₹44,982 Cr.
Glaxosmithkline Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Glaxosmithkline Pharmaceuticals Ltd. has a P/E of 43.4 and a return on equity of 48.91%.
Glaxosmithkline Pharmaceuticals Ltd. is listed on the BSE under the scrip code 500660.
Glaxosmithkline Pharmaceuticals Ltd.'s share price is up 3.3% over one year and up 0.2% over three months. Its 52-week range is ₹2,088.10 to ₹3,120.70.
In Q2 FY27, Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹1,184 Cr and net profit of ₹336 Cr, with basic EPS of ₹19.83 (consolidated, parsed from the company's exchange filing).
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹1,184 Cr in Q2 FY27, up 20.8% from ₹980 Cr in Q2 FY26 and up 26.1% from ₹938 Cr in Q1 FY27.
Promoters held 75.00% of Glaxosmithkline Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.